SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, filed on Thursday with the SEC to raise up to $55 million in an initial public offering. The Durham, NC-based company, which was founded in 1999 and booked $17 million in research services and licensing revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.
